At a glance
- Originator Yamanouchi
- Class Antineoplastics
- Mechanism of Action Steroid 17-alpha-hydroxylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 26 Jun 2001 No-Development-Reported for Prostate cancer in Japan (Unknown route)
- 13 Jan 1998 Preclinical development for Prostate cancer in Japan (Unknown route)